Möchten Sie immer auf dem neuesten Stand bleiben?

Initial results of a Phase 1 / 2 open label study of AT-02, the company’s lead pan-amyloid removal therapeutic candidate, in patients with AL amyloidosis will be presented at ASH.The presentation...

124I-evuzamitide, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis of cardiac amyloidosis in patients suspected of or diagnosed with...

124I-evuzamitide (AT-01) PET/CT, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis of cardiac amyloidosis in patients suspected or...

Phase 3 – REVEAL study for iodine 124I-evuzamitide (AT-01) in patients with suspected cardiac amyloidosis has begun enrollment by Brigham and Women’s Hospital, Boston MA, in conjunction with...

NAPLES, Fla., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines and diagnostics to improve the lives of patients with...

124I-evuzamitide (AT-01) is one of the first investigational diagnostic imaging agents to receive Breakthrough Therapy Designation (BTD) from the US Food and Drug Administration (FDA), and the only...

AT-02 has been granted COMP positive opinions for orphan medicinal product designations in the EU for both ATTR and AL amyloidosisAT-02 is the Company’s lead pan-amyloid removal therapeutic candidate...

AT-02, the company’s lead pan-amyloid removal therapeutic candidate, is currently being evaluated in a Phase 1 three-part trial and a Phase 2 open label extension trial in ATTR and AL amyloidosis...

Attralus, Inc. today announced that it has closed a $56 million financing.

124I-evuzamitide shown to be highly accurate for detection of cardiac amyloid across two independent investigator-initiated studies.124I-evuzamitide detects multiple types of systemic...